Systemic sclerosis: A systematic review on therapeutic management from 2011 to 2014

Current Opinion in Rheumatology

Volumn 27, Issue 3, 2015, Pages 241-248

  Young, Amber ^a   Khanna, Dinesh ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Nonpharmacological; Pharmacological; Systemic sclerosis; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

BIOLOGICAL THERAPY; EXTRACORPOREAL LITHOTRIPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; META ANALYSIS (TOPIC); METHODOLOGY; MOUTH HYGIENE; MUSCULOSKELETAL SYSTEM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA RENAL CRISIS; STOMACH PARESIS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE; DISEASE MANAGEMENT; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC;

DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84926335197     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000172     Document Type: Review

References (49)

1. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) 2014. [Epub ahead of print]
2. Quillinan NP, McIntosh D, Vernes J, et al. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): A phase II doubleblind placebo-controlled trial. Ann Rheum Dis 2014; 73:56-61.
3. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010; 2:863-878.
4. Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013; 31 (Suppl 76):151-156.
5. Chung L, Denton CP, Distler O, et al. Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol 2012; 30 (2 Suppl 71):S97-S102.
6. Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015; 42:236-242.
7. Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in sclerodermaassociated diffuse skin fibrosis: A phase II multicentre randomized doubleblinded controlled trial. Br J Dermatol 2012; 167:1138-1144.
8. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63:3547-3551.
9. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70:1003-1009.
10. PhumethumV, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: A systematic review. J Rheumatol 2011; 38:289-296.
11. Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015; 44:428-436.
12. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014. [Epub ahead of print]
13. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39:1241-1247.
14. Le EN1, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70:1104-1107.
15. Tinazzi E, Amelio E, Marangoni E, et al. Effects of shock wave therapy in the skin of patients with progressive systemic sclerosis: A pilot study. Rheumatol Int 2011; 31:651-656.
16. Yuen HK, Weng Y, Bandyopadhyay D, et al. Effect of a multifaceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol 2011; 29 (2 Suppl 65):S26-S32.
17. Yuen HK, Marlow NM, Reed SG, et al. Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil 2012; 34:84-89.
18. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study. Ann Rheum Dis 2013; 72:1217-1220.
19. Piga M, Tradori I, Pani D, et al. Telemedicine applied to kinesiotherapy for hand dysfunction in patients with systemic sclerosis and rheumatoid arthritis: Recovery of movement and telemonitoring technology. J Rheumatol 2014; 41:1324-1333.
20. Poole JL, Skipper B, Mendelson C. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis. Clin Rheumatol 2013; 32:1393-1398.
21. Volkmann ER, Saggar R, Khanna D, et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014; 66:1900-1908.
22. Rubenfire M, Huffman MD, Krishnan S, et al. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest 2013; 144:1282-1290.
23. Johnson SR, Granton JT, Tomlinson GA, et al. Warfarin in systemic sclerosisassociated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39:276-285.
24. Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013; 107:2081.
25. Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev 2013; 22:515-525.
26. Becker MO, Schohe A, Weinert K, et al. Responders to cyclophosphamide: Results of a single-centre analysis among systemic sclerosis patients. Ann Rheum Dis 2012; 71:2061-2062.
27. Espinosa G, Simeó n CP, Plas̈n MÁ, et al. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol 2011; 47:239-245.
28. Domiciano DS, Bonfá E, Borges CT, et al. A long-term prospective randomized controlled study of nonspecific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011; 30:223-229.
29. Abhishek A, Yazdani R, Pearce F, et al. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clin Rheumatol 2011; 30:1099-1104.
30. Poormoghim H, Moradi Lakeh M, Mohammadipour M, et al. Cyclophosphamide for scleroderma lung disease: A systematic review and meta-analysis. Rheumatol Int 2012; 32:2431-2444.
31. Poormoghim H, Rezaei N, Sheidaie Z, et al. Systemic sclerosis: Comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int 2014; 34:1691-1699.
32. Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63:3540-3546.
33. Fraticelli P, Gabrielli B, Pomponio G, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: A phase II pilot study. Arthritis Res Ther 2014; 16:R144.
34. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. JAMA 2014; 311:2490-2498.
35. Burt RK, Shah SJ, Dill K, et al. Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet 2011; 378:498-506.
36. Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell transplantation for systemic sclerosis: A single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012; 39:269-275.
37. Khanna D, Georges GE, Couriel DR. Autologous hematopoietic stem cell therapy in severe systemic sclerosis: Ready for clinical practice? JAMA 2014; 311:2485-2487.
38. Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and metaanalysis of randomised trials. Ann Rheum Dis 2013; 72:1696-1699.
39. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011; 63:775-782.
40. Lee EY, Park JK, Lee W, et al. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: A doubleblind, randomized, cross-over study. Rheumatology (Oxford) 2014; 53:658-664.
41. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013; 65:1460-1471.
42. Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma. J Hand Surg Eur Vol 2014; 39:876-880.
43. Moran ME. Scleroderma and evidence based nonpharmaceutical treatment modalities for digital ulcers: A systematic review. JWound Care 2014; 23:510-516.
44. Sporbeck B, Mathiske-Schmidt K, Jahr S, et al. Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: Results of a controlled prospective randomized clinical trial. Rheumatol Int 2012; 32:1469-1473.
45. Montanelli G, Beretta L, Santaniello A, Scorza R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013; 31 (Suppl 76):135-139.
46. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: A systematic review. Rheumatol Int 2012; 32:645-653.
47. Hudson M, Baron M, Tatibouet S, et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014; 43:666-672.
48. Ariyasu H, Iwakura H, Yukawa N, et al. Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. Endocr J 2014; 61:735-742.
49. Sallam HS, McNearney TA, Chen JD. Acupuncture-based modalities: novel alternative approaches in the treatment of gastrointestinal dysmotility in patients with systemic sclerosis. Explore (NY) 2014; 10:44-52.